Information:
Fel:
ID
34169
Beskrivning
Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01395056
Länk
https://clinicaltrials.gov/show/NCT01395056
Nyckelord
Versioner (1)
- 2019-01-15 2019-01-15 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
15 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Breast Neoplasms NCT01395056
Eligibility Breast Neoplasms NCT01395056
- StudyEvent: Eligibility
Similar models
Eligibility Breast Neoplasms NCT01395056
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
failure to anthracycline and/or taxol chemotherapy;
boolean
ID.2
Item
metastatic tumor is histologically confirmed by immunohistochemical staining to be er-negative and pr-negative. fish testing for her-2-negative;
boolean
ID.3
Item
metastatic tumor can not be removed through surgery procedure;
boolean
ID.4
Item
an eastern cooperative oncology group (ecog) performance status of 0-2;
boolean
ID.5
Item
normal cardiac, hepatic, renal and bone marrow functions;
boolean
ID.6
Item
life expectancy ≥3 months.
boolean
ID.7
Item
central nervous system metastases;
boolean
ID.8
Item
serious or uncontrolled concurrent medical illness;
boolean
ID.9
Item
history of other malignancies;
boolean
ID.10
Item
having been enrolled in some other clinal trials within a month;
boolean